Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295770 · ClinicalTrials.gov registry record · Phase 2
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
A Phase 2 study of Fibrillary Glomerulonephritis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06295770: Recruiting Phase 2 study of Fibrillary Glomerulonephritis, sponsored by Mayo Clinic.
NCT06295770 is a Phase 2 study of Fibrillary Glomerulonephritis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06295770, a Phase 2 study of Fibrillary Glomerulonephritis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Primary Outcome
Measured using 24-hour urine collection reported in mg/24h
Conditions Studied
Interventions
- DRUG Obinutuzumab
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06295770 shows while recruiting
NCT06295770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Fibrillary Glomerulonephritis appearing as the primary indexed condition, and to 1 intervention - of which Obinutuzumab is the first listed.
NCT06295770 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06295770 about?
NCT06295770 is a clinical study titled "Obinutuzumab in Treatment of Fibrillary Glomerulonephritis". The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
What is the current status of trial NCT06295770?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-06-24. Estimated completion is 2026-05.
What conditions does trial NCT06295770 study?
This clinical trial studies the following conditions: Fibrillary Glomerulonephritis.
What interventions are being tested in trial NCT06295770?
The interventions under investigation include: Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT06295770?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295770 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06295770's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI